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SUMMARY So far brain metastases represent a critical stage of a disease course and 
the frequency is increasing over the years. The treatment of brain metastases should be 
individualized for each patient: in case of single brain metastasis, surgery or radiosurgery 
should be considered as first options of treatment; in case of multiple lesions, whole-
brain radiotherapy is the standard of care in association with systemic therapy or surgery/
radiosurgery. Chemotherapy should be considered when surgery or radiation therapy are 
not possible. In the last decades, TKIs or monoclonal antibodies have shown increase in 
overall response rate and overall survival in Phase II–III trials. The aim of this paper is to make 
an overview of the current approaches in management of patients with brain metastases.
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Brain metastases (BMs) are the most frequent cause of malignant tumor of the central nervous 
system (CNS), four-times higher than primary tumors; about 20–40% of patients with cancer 
will develop BM in their clinical course. Furthermore, the frequency of BM is increasing over the 
years as a result of the increase in overall survival (OS) in cancer patients and of the improvement 
in diagnostic tools for BM detecting, as magnetic resonance imaging (MRI). Primary tumors that 
most frequently metastasize to brain are in order of frequency: lung (≥50%), breast (15–25%), 
melanoma (5–20%) and, less frequently, testis, kidney, colon–rectum, thyroid, but more in general 
any cancer subtype can metastasize to the brain. In 15% of cases, the primary site is unknown. BMs 
usually develop in advanced stages of disease, less frequently BMs are the first clinical sign of cancer 
and/or synchronous with primary tumor diagnosis. The most recent data in the literature describe 
a modification of this scenario, in particular, a recent study by Nieder et al. [1] brings out a clear 
difference in the presentation of patients with BM between the period 1983–1989 and 2005–2009. 
Over time it has been described a greater representation of the female sex (due to a high prevalence 
of BM from breast cancer), an increase in the number of diagnosis of BM and a lengthening of the 
interval between the diagnosis of primary tumor and BM detection [2]. Inside the brain the most 
common sites of metastasis are: cerebral hemispheres (80%), cerebellum (15%) and basal nuclei 
(about 5–10%) [2]. The clinical presentation of the patient with BM is similar to patients with pri-
mary tumors: intracranial hypertension (space-occupying mass), headache, seizures and/or focal 
neurological symptoms. Headache is the presenting symptom in 40–50% of patients, often secondary 
to increased intracranial pressure [3]. Focal neurological deficits, such as hemiparesis, aphasia and 
hemianopia are observed in 40% of cases and in 15–20% of patients seizures are the first symptom. 
In some cases, BMs have a clinical presentation similar to an acute stroke, often correlated to an intra-
tumoral hemorrhage (melanoma, renal cell carcinoma) or to a transient ischemic attack [4,5]. Patients 
with multiple metastases and/or intracranial hypertension could have an altered mental state and 
cognitive slowing, as in case of metabolic encephalopathy. With best supportive care only, median 
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overall survival time is 1–3 months; radiation 
therapy (RT) increases survival 3–5 months. 
Up to now neurosurgical resection, if possible, 
and whole-brain radiotherapy (WBRT) are the 
mainstay of treatment.
Moreover surgery, stereotactic RT and/or sys-
temic treatments may improve survival, depend-
ing on cancer subtype, number of metastases and 
extracranial disease control.
Prognostic factors
The prognosis of patients with BM is gener-
ally poor and significantly impairs patients 
quality of life, median survival of patients 
with BM does not usually exceed 5 months 
despite the current treatment options avail-
able. Nevertheless, the definition of well rec-
ognized prognostic subgroups is essential for 
the choice of a tailored therapeutic strategy. It 
is important to identify subgroups of patients 
with favorable prognostic factors that can ben-
efit from an intensive treatment with the goal of 
improving survival and quality of life. On the 
contrary in patients without an optimal extra-
cranial disease control and/or co-morbidities 
(that could limit the tolerability of aggressive 
treatments), treatment goal is to stabilize BM, 
to control symptoms and to limit toxicity. The 
most important prognostic factors are key per-
formance status (KPS), the number of BM, 
absence of systemic metastases, primary tumor 
control and age. The ‘Radiotherapy Oncology 
Group’ (RTOG) designed a prognostic scor-
ing system derived from the analysis of inde-
pendent prognostic factors for patients with 
BM and identified three different sub-groups 
(RPA classes) (Table 1) [6]. It was subsequently 
developed a new and more detailed prognostic 
index (Graded Prognostic Assessment, GPA) 
that takes into account four variables: age, KPS, 
presence of extra-cerebral metastases and num-
ber of BM (Tables 2 & 3) [7,8]. Recently updates 
were published with ref inements to create 
 diagnosis-specific GPA indices [9].
Diagnosis
In the evaluation of brain tumors (primary and 
BM), magnetic resonance imaging (MRI) is 
superior to CT scan. MRI is able to detect a 
greater number of lesions and to better define 
their pattern (site, dimensions, characteristics): 
almost 1/3 of patients with single lesion at CT 
have multiple metastases on MRI [10]. CT may 
have a role in identifying bone lesions or to 
exclude hemorrhage within the lesion [11].
In the clinical work-up of a patient with a 
single BM, a contrast enhanced MRI should 
be considered to exclude the presence of other 
smaller lesions and to better define the correct 
therapeutical approach [12]. In case of diagno-
sis of a single brain lesion at MRI (i.e., done 
for neurological symptoms) and no history of 
cancer, the patient must be submitted to a con-
trast-enhanced chest and abdomen CT and/or 
PET-CT to detect the primary tumor outside 
the CNS or to highlight other neoplastic lesions, 
more easily approachable for the histotype char-
acterization. If CT or PET-TC do not detect any 
neoplastic lesions outside the CNS, a neurosur-
gical approach to obtain histological diagnosis 
must be considered.
The surgical excision or stereotactic biopsy 
for diagnostic confirmation might be considered 
in doubtful cases also in patients with a known 
history of cancer.
Supportive care
Steroids, in particular dexamethasone, have 
the greatest initial clinical impact on quality 
of life in patients with BM. Typically, within 
the first 24 h after the introduction of steroid 
treatment, an improvement in neurological 
symptoms is shown. The clinical improve-
ment is achieved even before the reduction 
of brain edema and this is due to the effect 
on the reduction of the permeability of the 
blood–brain barrier [13]. In patients without 
signs of intracranial hypertension, low doses 
of dexamethasone have similar efficacy than 
Table 1. The radiotherapy oncology group prognostic classification.
Classes Prognostic factors Median survival (months)
I KPS ≥70, controlled primary tumor, age <65 years, 
nonextracranial metastatic disease
7.1
II KPS ≥70, primary tumor not controlled or age 65 years, or 
extracranial metastatic disease
4.2
III KPS <70 2.3
Key: Key performance status.
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higher doses and the clinical improvement 
based on KPS is similar [14]. Therefore, after 
the diagnosis of BM, the steroid treatment is 
recommended, even in the absence of symp-
toms because of the risk of rapid clinical dete-
rioration. The dose of dexamethasone is modu-
lated according to response to treatment and 
the patient’s condition, and the aim is to iden-
tify the lowest effective dose. The initial dose 
should be 4 mg/day/orally, up to 16 mg/day in 
cases of brainstem or cerebellum BM or altered 
state of consciousness or other signs of intracra-
nial hypertension [15]. Prophylactic antiepileptic 
therapy does not reduce the onset of seizures, 
then there is no indication to its use. Treatment 
should be started only in symptomatic patients 
[16,17]. The enzyme-inducing antiepileptic 
drugs (enzyme-inducing antiepileptic drugs 
[EIAEDs]), metabolized by P450 cytochrome 
(such as phenytoin, carbamazepine and phe-
nobarbital) should be avoided, if possible, 
as it may cause significant drug interactions 
with chemotherapeutic agents (i.e., CPT-11, 
nitrosoureas, navelbine, teniposide, vinblas-
tine, paclitaxel, cyclophosphamide, ifosfa-
mide, topotecan, thiotepa, doxorubicin and 
methotrexate) and with biological drugs (i.e., 
imatinib, gefitinib and erlotinib).
Principles of treatment
The treatment of BM should always be indi-
vidualized for each patient, according to the 
different sensitivity of the primary cancer to 
RT and/or chemotherapy (CT), the different 
clinical history (extracranial disease control, pre-
vious treatments, survival, disease-free interval) 
[17] and especially to the number of metastases. 
A multidisciplinary discussion of each case 
from diagnosis to treatment planning is always 
recommended.
Single brain metastasis
Only 10% of patients presented with a single 
BM and only 50% of these patients are resect-
able. Surgical resection immediately improves 
symptoms of intracranial hypertension, focal 
neurological deficits and seizures and reduces 
the need for steroid. Two of three randomized 
trials that compared WBRT alone to surgery 
followed by radiotherapy have shown a benefit 
in terms of survival of patients treated with sur-
gery compared with radiotherapy alone (median 
survival of 10.9 vs 6.3 months) and a reduction 
in local recurrence rate from 52% for surgical 
patients to 20% for RT patients. The third 
study did not show a benefit in survival for sur-
gical patients, but a greater number of patients 
with active systemic disease and poor perfor-
mance status were included [18–21]. Therefore, 
surgery is the option of choice in the case of 
single metastasis in patients with extracranial 
controlled disease and good performance status 
(KPS ≥ 70).
Stereotactic radiosurgery (SR) (using gamma 
knife or linear accelerator) has the goal to limit 
the risk of damage to the surrounding healthy 
brain tissue and it is characterized by the admin-
istration of a single fraction of radiotherapy at 
higher dose. Target lesions might have a maxi-
mum diameter of 3–3.5 cm and might be located 
at any site inside the brain. The local control at 
1 year ranges from 80 to 90% with a median 
survival of 6–12 months. SR might be purposed 
even in BM from radioresistant tumors such 
as melanoma, renal cell carcinoma and colon 
 cancer [22–26].
Table 2. Graded prognostic assessment classification.
Variable Score = 0 Score = 0.5 Score = 1
Age (years) >60 50–59 <50
Key performance status <70 70–80 90–100
Number of brain metastases >3 2–3 1
Extra-cranial metastases Present  None Absent
Table 3. Outcome of the scores from graded prognostic assessment classification.
Score Median survival (months) 
0–1 2.6
1.5–2.5 3.8
3 6.9
3.5–4 11
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A randomized trial showed that the addition 
of SR to WBRT improves survival of patients 
with unresectable single metastasis at diagno-
sis [27]. Moreover, SR can be effective as sav-
age treatment in recurrences after WBRT [28]. 
Nevertheless, up to now literature data are not 
so solid to show if SR might replace surgery in 
the treatment of single BM [29]. Currently, the 
choice between surgery and SR depends on mul-
tiple factors, including size and location of the 
lesion to be treated, but also extracerebral dis-
ease control and performance status. The role of 
adjuvant WBRT (30–40 Gy in 2–3 weeks) after 
surgery or SR is controversial: adjuvant WBRT 
after surgical resection or SR reduces intracra-
nial relapses, maintaining a better neurological 
 function, but does not influence survival [30].
In case of larger lesions, stereotactic radio-
therapy (SRT) of BM should be an alternative 
option and differs from SR for the dose used per 
fraction and for the duration of treatment, longer 
than in case of SR [31].
Multiple brain metastases ≤3
No randomized studies regarding the use of sur-
gery on multiple metastases have been published, 
although it can be proposed for selected patients. 
A complete surgical resection might be purposed 
in case of younger patients, good KPS, surgi-
cally feasible, limited number of lesions (≤3) 
and controlled systemic disease. In these selected 
cases, the efficacy of surgery in achieving a local 
 control is similar than in a single BM [32].
SR is used as an alternative to WBRT in 
patients with a number of metastases equal to 
or less than 3, in good KPS and with controlled 
systemic disease. For smaller lesions (<2.5 cm), 
SR may be a possible therapeutic alternative to 
surgery, whether or not followed by WBRT. 
In selected patients with multiple BM (up 
to 3 or 4, in a randomized study) and small 
lesions (<4 cm), the addition of SRT to WBRT 
improves local control of disease but not survival 
[25] In patients with good KPS and controlled 
extracranial disease, the role of adjuvant WBRT 
after locoregional treatment is similar than in 
patients with single BM [33].
In case of patients with active systemic dis-
ease and/or poor KPS, WBRT alone achieves 
a median survival of 3–6 months and may be 
the treatment of choice. There is no evidence to 
support the choice of any particular dose/frac-
tionation regimen based on histopathology [34]. 
Soffietti et al. recently published the results of an 
EORTC study regarding quality of life (QoL) in 
patients with BM (up to 3) treated with adjuvant 
(postsurgery or RS) WBRT versus observation: 
the study showed that WBRT may negatively 
impact on some aspects of health-related QoL, 
even if they are transient. Observation with neu-
roradiological close follow-up is not detrimental 
on health-related QoL [35].
Multiple brain metastases >3
The role of surgery is more restricted in this con-
dition and aimed at obtaining the diagnosis if the 
primary site of disease is unknown or as treat-
ment in case of larger lesions causing mass effect. 
In selected cases with newly diagnosed BM, SR 
alone could be an option, because it is compa-
rable to WBRT in terms of survival. However, 
the omission of WBRT after SR reduces the 
intracranial disease control with no differences 
in overall survival [36]. Quality of life in terms of 
neurocognitive function after treatment with RS 
or WBRT (with or without RS) is unknown and 
never been adequately tested. However, there is a 
statistically significant difference in overall toxic-
ity in patients treated with SR alone if compared 
with patients treated with WBRT plus stereo-
tactic boost (based on an interim analysis of a 
single randomized trial) [37]. The clinical ben-
efits/risks associated with the use of SR in case of 
progression or recurrence of BM is not supported 
by strong evidence. Based on these considera-
tions, the use of SR as salvage therapy can only 
be considered as an option in selected patients 
with controlled extracranial disease and good 
KPS [28]. WBRT (30–40 Gy in 10–15 daily frac-
tions) is the standard treatment for patients with 
multiple BM greater than 3, prolonging median 
survival from 3 to 6 months and proving good 
control of symptoms. Higher doses of RT do not 
increase survival or local control. Moreover, daily 
fractions higher than 3 Gy may increase the risk 
of neurotoxicity [38]. Retrospective studies have 
shown that nearly 50% of patients treated with 
WBRT die for systemic progression rather than 
for brain disease. The available literature data 
on the decline of neurocognitive function after 
WBRT are limited. Despite the fact that thera-
peutic approach is influenced by the decline in 
neurocognitive function after WBRT in long 
survivors [39,40], more recent studies have sug-
gested that neurocognitive function is strongly 
and mainly influenced by the brain tumor con-
trol [41]. In patients with KPS less than 70, best 
supportive care is recommended.
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Radiosensitizers
A randomized Phase III study of association 
between a radiation sensitizer called motex-
afin–gadolinium (MGd) and WBRT in patients 
with BM from non-small-cell lung cancer 
(n = 554) showed that MGd is able to prolong 
the time to neurological progression from 8.8 
to 24.2 months (p = 0.004; HR = 0.53), with 
 acceptable toxicity [42].
Chemotherapy
Systemic therapy is rarely used as first-line 
approach in patients with BM, especially as 
single treatment (Table 3). Patients with BM 
from chemosensitive tumors (lung, breast, tes-
ticle) should always be evaluated for surgery in 
relation to the number of BM and the extent/
control of systemic disease. BM presents often 
the same chemo-responsiveness of the primary 
tumor or extracranial metastases; however, the 
limited drug levels crossing the blood–brain 
barrier, the possible interaction with concomi-
tant therapies (i.e., AEDs and EIAEDs) and the 
possible increased resistance of the neoplastic 
cells in BM (i.e., due to genotypic or molecular 
alterations) may be limiting factors. For these 
reasons, chemotherapy is usually considered as 
the last therapeutic option when surgery or RT 
are not possible g [43]. The choice and efficacy 
of chemotherapy depend on chemosensitivity of 
the primary tumor. In patients not suitable for 
surgery, although systemic chemotherapy can 
achieve objective responses, the use of WBRT 
is extremely important [44,45]. In a large variety 
of non-small-cell lung cancer (NSCLC) trials, 
chemotherapy has shown the same response 
rates in cranial and extracranial disease [46]. For 
example, in a Phase III study, fotemustine has 
shown an increase in response rate and time to 
progression when compared with dacarbazine in 
patients with BM from melanoma [47]; moreover, 
fotemustine has shown an increase in response 
rate also in association with cisplatin in BM 
from NSCLC [48]. Temozolomide has shown 
some efficacy in patients with chemo-naive BM 
from melanoma [49]. In some randomized stud-
ies, several different chemotherapeutic agents, 
including carboplatin and temozolomide, have 
been used in addition to WBRT in the treatment 
of patients with BM from NSCLC and breast 
cancer: these studies reported an increased local 
disease control, but no differences in overall sur-
vival [50,51]. Therefore, their use can be consid-
ered in patients with favorable prognostic factors, 
in absence of systemic disease progression. In 
patients with BM only after chemotherapy for an 
extra CNS disease, the benefit obtained with fur-
ther chemotherapy is not significant, but it can 
be considered in case of chemosensitive forms in 
combination with radiotherapy. The combined 
chemo- and radiotherapy may improve response 
rate and progression-free survival, not overall 
survival [52,53]. Prophylactic WBRT for patients 
with small-cell lung cancer in complete response 
to chemotherapy is the standard treatment and it 
can reduce the risk of developing BM from 59 to 
33% in 3 years and increase the 3-year survival 
from 15 to 21% [54].
Targeted therapies
Targeted therapies (TT) have been initially 
employed in extra- central nervous system 
(CNS) disease, more recently in BM patients 
(Table 4) [55,56]. Most clinical trials with target 
therapies in BM enrolled patients with CNS 
disease progression after WBRT and limited 
clinical data support the prevention instead of 
the treatment of BM.
Among TT, both monoclonal antibodies 
and small molecules have been tested. Several 
Phase I–II trials with anti-VEGF and in par-
ticular bevacizumab (already approved in colo-
rectal cancer, ovarian cancer, metastatic renal 
 carcinoma) are ongoing [57–62].
Ipilimumab (anti-CTLA-4 monoclonal anti-
body), approved as first line therapy in metastatic 
melanoma, has been studied in a Phase II trial 
in patients with BM from melanoma: among 
51 patients, 9 (18%) achieved a disease control 
in both extra-CNS and CNS disease [63].
In the last decade, a large variety of Phase I–II 
trial with TKIs gave us some answers about their 
efficacy in the treatment of BM.
Data on the use of sunitinib, an oral TKI that 
targets VEGFR 1–3 and PDGFR α-β approved 
in the treatment of metastatic renal cancer and 
GIST, derive from the expanded access program 
with an overall response rate (ORR) of 12% 
(26/213) among 213 patients with advanced 
renal cell carcinoma and BM [64]. However, 
sunitinib showed a marginal antitumor activity 
in a Phase II study in patients with previously 
irradiated BM from NSCLC with median PFS 
9.4 weeks and median (overall survival) OS 25.1 
weeks [65].
Sorafenib, an oral VEGFR and RAF-kinase 
inhibitor approved in HCC and metastatic renal 
carcinoma, seems to decrease the incidence of 
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BM in a post hoc analysis of patients enrolled in 
the treatment approaches in renal cancer global 
evaluation trial (TARGET) [66].
BM from NSCLC with activating EGFR 
mutations have been shown to respond to oral 
EGFR TKI’s gefitinib and erlotinib. They have 
similar efficacy profile achieving an ORR of 
10–38%, with a median duration of response 
of 9–13.5 months [67–73]. Up to now, no data 
are available on the activity of crizotinib (oral 
selective inhibitor of activated ALK) in the same 
setting.
In breast cancer, BM are frequently diagnosed 
in HER-2 positive or triple negative patients. 
The brain seems to be the first site of relapse 
in HER-2 positive patients treated with trastu-
zumab (anti-HER-2 monoclonal antibody) and 
biological subtypes are independent prognostic 
factors [74,75].
Lapatinib (an orally dual inhibitor of EGFR 
and HER-2 TKI used in metastatic breast can-
cer) reaches therapeutic levels in BM. Data of 
the lapatinib efficacy in patients with active BM 
have been published in several prospective trials 
[76,77]. However, there are not randomized trial 
comparing lapatinib versus radiotherapy alone: 
only one study analyzed the combination of lapa-
tinib + capecitabine prior to WBRT, showing 
an impressive CNS response rate [78]. This trial 
opens the door for studies comparing WBRT 
against capecitabine + lapatinib as first line in 
HER-2 positive patients with brain metastases.
In patients with BM from melanoma, sev-
eral Phase II trials with vemurafenib (a specific 
inhibitor of BRAF V600E mutated protein) 
are ongoing; preliminary results from a single-
arm pilot study are promising, showing a par-
tial response in patients with pretreated BM 
[79,80]. OR in extra-CNS and BM has also been 
described in a Phase I–II trial with dabrafenib 
(BRAF inhibitor) [81].
Follow-up treatment to relapse/
progression
Patients with BM should be controlled, espe-
cially if treated, using MRI every 3 months dur-
ing the first year, then if clinically indicated. The 
treatment of recurrent disease is directly related 
to previous treatments, histotype, extra-CNS 
disease control and KPS. If the disease pro-
gresses locally (failure on local control disease), 
patients previously treated with surgery could be 
Table 4. Chemotherapy in brain metastases.
Chemotherapy Study Phase of trial Patient population Patients (n) ORR OS (months)
Fotemustine vs DTCI Avril et al. [47] III Melanoma 112 15.2% 7.3
Temozolomide Agarwala et al. [49] II Melanoma 151 7% 3.5
Fotemustine + CDDP Cotto et al. [48] II NSCLC 31 28% 4.0
CBDCA + RT vs RT Guerrieri et al. [50] III NSCLC 21 29% 3.7
CDDP + VP16  Franciosi et al. [46] II Breast, NSCLC, melanoma 43 30% 8.0
Temozolomide + WBRT vs WBRT Verger et al. [51] II Brain metastases 41 17% 4.5
Temozolomide + WBRT vs WBRT Antonadou et al. [52] II Brain metastases 25 96% 8.6
NSCLC: Non-small-cell lung cancer; ORR: Overall response rate; OS: Overall survival; RT: Radiation therapy; WBRT: Whole-brain radiotherapy.
Table 5. Target therapies in brain metastases.
Agent Study Phase of trial Patient population Patients (n) ORR (%) OS (months)
Bevacizumab + VP16 + CDDP Lu et al. [59] II Breast 16 75 Ongoing
Bevacizumab + CBDCA Lin et al. [60] II Breast 38 45 Ongoing
Lapatinib Lin et al. [76] II Breast 39 3 6.0
Lapatinib + Xeloda Bachelot et al. [78] II Breast 45 66 17.0
Sunitinib Gore et al. [64] III mRCC 321 12 9.2
Sorafenib Massard et al. [66] III mRCC 139 NA 8.9
Sunitinib Novello et al. [65] II NSCLC 64 1.6 6.0
Gefitinib Ceresoli et al. [67] II NSCLC 41 9.7 5.0
Gefinitib Wu et al. [68] II NSCLC 40 32 15.0
Erlotinib + RT Welsh et al. [69] II NSCLC 40 86 11.8
Vemurafenib Dummer et al. [80] II Melanoma 24 42 5.3
Ipilumumab Margolin et al. [63] II Melanoma 72 16–5 7–3.7
 NA: Not available; NSCLC: Non-small-cell lung cancer; ORR: Overall response rate; OS: overall survival; RT: Radiation therapy; WBRT: Whole-brain radiotherapy.
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Figure 1. Treatment algorithm.
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treated with surgery again, RS, SRT or systemic 
chemotherapy.
If the disease progresses to other locations 
regardless of the presence of local recurrence or 
not, patients not previously treated with WBRT 
should receive this treatment and a systemic 
therapy based on histotype. If the KPS is poor 
and there are no further treatment options are 
available, best supportive care alone may be the 
only acceptable strategy.
Conclusion & future perspective
The treatment of BM is still controversial, espe-
cially in some setting of patients. Aim of the pre-
sent study is to review literature and try to suggest 
a possible work-up for these patients (Figure 1).
In particular, we highlighted the importance 
of a multidisciplinary discussion for the choice 
of a tailored treatment based on patients char-
acteristics. Surgery and radiotherapy have a con-
solidated role in this setting. Only few drugs 
EXEcUtiVE SUMMARY
Background
 ●  The frequency of brain metastases is increasing over the years.
 ●  The treatment of brain metastases should be individualized for each patients based on multiple prognostic factors.
 ●  Systemic treatment with steroids is the first step at diagnosis of symptomatic brain metastases.
Local treatment
 ●  In case of single brain metastasis, surgery o radiosurgery should be considered as first options of treatment.
 ●  In case of multiple brain metastases less than equal to 3, a complete surgical resection might be purposed in case of 
good prognostic factors and controlled systemic disease.
 ●  In case of multiple brain metastases greater than 3, whole-brain radiotherapy is the standard of care in association with 
systemic therapy or surgery/radiosurgery.
Systemic treatment
 ●  Chemotherapy has limited efficacy on brain metastases and is usually considered as the last therapeutic option when 
surgery or radiation therapy are not possible.
 ●  In the last decades, novel agents such as tyrosine kinase inhibitors or monoclonal antibodies have shown increase in 
overall response rate and overall survival in Phase II–III trials.
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may reach proper concentrations within the 
CNS and efficacy of systemic therapies is lim-
ited. Actually few data on the clinical activity 
of targeted agents are available, but novel agents 
as TKI’s or monoclonal antibodies have shown 
increase in ORR and OS in Phase II–III trials.
In the immediate future, it would be hopeful 
that new molecules may demonstrate efficacy 
and may take a leading role alone or in combina-
tion with locoregional therapies in treatment of 
BM patients (Table 5).
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